Greenwich LifeSciences, Inc.
GLSI
$16.80
$0.422.56%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.21% | 4.14% | -65.31% | 49.45% | -0.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.69% | 106.80% | -18.17% | 52.97% | 41.63% |
| Operating Income | -6.69% | -106.80% | 18.17% | -52.97% | -41.63% |
| Income Before Tax | -5.34% | -106.10% | 18.03% | -55.57% | -43.81% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.34% | -106.10% | 18.03% | -55.57% | -43.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.34% | -106.10% | 18.03% | -55.57% | -43.81% |
| EBIT | -6.69% | -106.80% | 18.17% | -52.97% | -41.63% |
| EBITDA | -6.71% | -106.85% | 18.17% | -53.02% | -41.64% |
| EPS Basic | 3.67% | -86.37% | 22.75% | -49.88% | -38.81% |
| Normalized Basic EPS | 3.65% | -86.48% | 22.76% | -49.88% | -38.83% |
| EPS Diluted | 3.67% | -86.37% | 22.75% | -49.88% | -38.81% |
| Normalized Diluted EPS | 3.65% | -86.48% | 22.76% | -49.88% | -38.83% |
| Average Basic Shares Outstanding | 9.35% | 10.58% | 6.11% | 3.80% | 3.60% |
| Average Diluted Shares Outstanding | 9.35% | 10.58% | 6.11% | 3.80% | 3.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |